Additive pharmacological interaction between sirtuin inhibitor cambinol and paclitaxel in MCF7 luminal and MDA-MB-231 triple-negative breast cancer cells.

Wawruszak, Anna; Okon, Estera; Telejko, Ilona; Czerwonka, Arkadiusz; Luszczki, Jarogniew

Wawruszak, Anna; Okon, Estera; Telejko, Ilona; Czerwonka, Arkadiusz; Luszczki, Jarogniew.

Afiliação

Wawruszak A; Department of Biochemistry and Molecular Biology, Medical University of Lublin, Lublin, Poland. anna.wawruszak@umlub.pl.
Okon E; Department of Biochemistry and Molecular Biology, Medical University of Lublin, Lublin, Poland.
Telejko I; Department of Biochemistry and Molecular Biology, Medical University of Lublin, Lublin, Poland.
Czerwonka A; Department of Biochemistry and Molecular Biology, Medical University of Lublin, Lublin, Poland.
Luszczki J; Department of Pathophysiology, Medical University of Lublin, Lublin, Poland.

Pharmacol Rep ; 74(5): 1011-1024, 2022 Oct.

Article em En | MEDLINE | ID: mdl-35900723

Assuntos

Neoplasias da Mama; Sirtuínas; Neoplasias de Mama Triplo Negativas; Humanos; Feminino; Neoplasias de Mama Triplo Negativas/tratamento farmacológico; Paclitaxel/farmacologia; Inibidores de Histona Desacetilases/farmacologia; Inibidores de Histona Desacetilases/uso terapêutico; Neoplasias da Mama/tratamento farmacológico; Sirtuínas/farmacologia; Sirtuínas/uso terapêutico; Bromodesoxiuridina/farmacologia; Bromodesoxiuridina/uso terapêutico; Linhagem Celular Tumoral; Proliferação de Células; Ensaios Antitumorais Modelo de Xenoenxerto; Apoptose

Palavras-chave

Anticancer drugs; Breast cancer; Cambinol; Histone deacetylase inhibitor; Paclitaxel; Sirtuin inhibitor

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Sirtuínas / Neoplasias de Mama Triplo Negativas Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google